MarketCap
Facebook
X
Telegram
National HealthCare Corporation Financial Ratios 2025-2008 | NHC
Brief overview of National HealthCare Corporation's multiples and efficiency
Ratios are assessed across five available annual reports in the 2021–2025 interval.
The latest available valuation ratios are P/E 20.46x (median 20.46x), EV/EBITDA 16.24x (median 16.24x), P/S 1.62x (median 1.1x). Current valuation broadly matches recent historical reference points; the difference from five-year medians is 0%.
Earnings yield calculated as 1/P/E is about 4.9%, showing current profit per unit of share price.
End-period return metrics are ROE 11.2%, ROA 7.9%, ROCE 12%. Fundamental efficiency is balanced: profitability supports valuation but does not remove the need for future growth.
Price, earnings and growth produce a PEG of 1.26x, a neutral level if forecasts are realistic.
The cash return period is stable at 24.4 days initially and 26.8 days at the end.
What the ratios show
National HealthCare Corporation's valuation and business quality look relatively balanced, with no pronounced distortion in either direction.
Annual Financial Ratios National HealthCare Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
20.5 | 14.1 | 21.3 | 40.6 | 7.5 | 23.4 | 19.0 | 20.5 | 16.9 | 22.3 | 16.5 | 16.3 | 11.4 | 11.7 | 9.7 | 8.9 | 13.4 | - |
P/S |
1.6 | 1.1 | 1.2 | 0.8 | 1.0 | 1.0 | 1.3 | 1.2 | 1.0 | 1.2 | 1.0 | 1.0 | 0.9 | 0.9 | 0.8 | - | - | - |
EPS |
7.8 | 6.6 | 4.4 | 1.5 | 9.0 | 2.7 | 4.5 | 3.9 | 3.7 | 3.3 | 3.3 | 3.2 | 4.0 | 3.6 | 4.1 | 3.2 | 2.3 | - |
EV (Enterprise Value) |
2.81 B | 1.9 B | 1.72 B | 1.25 B | 1.42 B | 1.4 B | 1.76 B | 1.51 B | 1.28 B | 1.52 B | 1.25 B | 1.14 B | 945 M | 869 M | 811 M | 442 M | 496 M | -49 M |
EBITDA per Share |
11.2 | 8.57 | 6.5 | 4.7 | 5.97 | 5.89 | 6.19 | 6.74 | 6.69 | 6.84 | 7.69 | 7.57 | 7.69 | 6.95 | 7.75 | 6.2 | 5.63 | - |
EV/EBITDA |
16.2 | 14.4 | 17.3 | 17.3 | 15.5 | 11.2 | 13.3 | 11.9 | 9.7 | 11.8 | 9.0 | 7.7 | 6.2 | 6.4 | 5.3 | 5.2 | 6.5 | - |
PEG |
1.26 | 1.56 | 20.02 | -6.31 | -2.85 | -4.58 | 1.23 | 4.39 | 1.57 | 4.94 | 5.35 | -0.82 | 0.83 | -1.02 | 2.25 | - | - | - |
P/B |
2.3 | 1.5 | 1.6 | 1.0 | 1.1 | 1.2 | 1.7 | 1.7 | 1.4 | 1.7 | 1.4 | 1.2 | 1.1 | 1.0 | 1.0 | 0.6 | - | - |
P/CF |
13.3 | 13.4 | 12.8 | 104.3 | 16.6 | 4.8 | 17.6 | 17.6 | 15.3 | 39.8 | 56.4 | 38.8 | 12.5 | 15.8 | 10.8 | 7.4 | 6.3 | - |
ROE % |
11.23 | 10.40 | 7.35 | 2.57 | 15.26 | 5.25 | 8.76 | 8.04 | 8.00 | 7.55 | 8.42 | 7.27 | 9.39 | 8.79 | 10.47 | 9.49 | 7.62 | - |
ROA % |
7.86 | 6.69 | 5.10 | 1.76 | 9.88 | 3.07 | 5.30 | 5.45 | 5.13 | 4.65 | 5.08 | 4.97 | 6.59 | 6.30 | 7.40 | 6.35 | - | - |
ROCE % |
12.01 | 9.17 | 6.32 | 3.65 | 5.61 | 6.03 | 4.78 | 6.58 | 6.27 | 6.89 | 7.79 | 7.88 | 10.66 | 9.59 | 11.97 | 10.38 | 9.68 | - |
Current Ratio |
3.4 | 2.8 | 3.3 | 3.2 | 2.8 | 2.4 | 1.8 | 2.0 | 2.1 | 1.9 | 1.9 | 1.8 | 1.7 | 1.8 | 1.7 | - | - | - |
DSO |
33.0 | 34.0 | 33.3 | 33.0 | 31.6 | 32.4 | 35.6 | 36.7 | 35.4 | 35.6 | 35.3 | 35.2 | 39.8 | 41.5 | 34.6 | - | - | - |
DIO |
3.3 | 3.7 | 3.7 | 4.2 | 4.8 | 4.8 | - | - | - | - | - | - | - | - | 13.6 | 3.6 | - | - |
DPO |
9.6 | 10.1 | 9.3 | 10.5 | 11.9 | 11.8 | - | - | - | - | - | - | - | - | 18.1 | 5.0 | - | - |
Operating Cycle |
36.3 | 37.7 | 37.0 | 37.1 | 36.3 | 37.2 | - | - | - | - | - | - | - | - | 48.3 | 3.6 | - | - |
Cash Conversion Cycle |
26.8 | 27.7 | 27.8 | 26.6 | 24.4 | 25.4 | - | - | - | - | - | - | - | - | 30.2 | -1.4 | - | - |
All numbers in USD currency
Quarterly Financial Ratios National HealthCare Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
2.58 | 2.31 | 2.53 | 1.53 | 2.09 | - | 2.78 | 1.74 | 1.71 | - | 0.68 | 1.06 | 0.76 | - | -0.16 | 0.21 | 0.99 | - | -0.22 | 6.83 | 1.39 | - | 0.84 | 1.85 | -1.76 | 0.91 | 1.27 | 0.9 | 1.39 | 1.19 | 1.39 | 1.47 | -0.18 | 1.41 | 0.75 | 0.7 | 0.84 | 0.92 | 0.73 | 0.78 | 0.92 | 1.03 | 0.75 | 0.74 | 0.8 | 0.92 | 0.77 | 0.75 | 0.8 | 1.04 | 1.28 | 0.88 | 0.84 | 0.99 | 1.08 | 0.82 | 0.76 | 0.89 | 1.09 | 0.83 | 1.21 |
EBITDA per Share |
4.59 | 2.82 | 2.68 | 2.92 | 2.7 | - | 2.17 | 2.07 | 1.71 | - | 1.51 | 1.57 | 1.31 | - | 0.93 | 0.94 | 1.56 | - | 2.82 | 1.56 | 1.66 | - | 2.52 | 2.19 | 1.72 | 1.08 | 2.49 | 2.03 | 1.72 | 1.13 | 2.76 | 2.16 | 1.72 | 1.07 | 2.72 | 2.17 | 1.72 | 1.17 | 2.59 | 2.19 | 1.81 | 1.35 | 2.99 | 1.81 | 1.92 | 1.43 | 1.69 | 1.78 | 1.8 | 1.41 | 1.9 | 1.74 | 1.66 | 1.45 | 1.73 | 1.72 | 1.6 | 1.19 | 1.83 | 1.75 | 2.4 |
ROE % |
12.93 | 12.54 | 13.59 | 12.69 | 13.20 | 10.00 | 11.17 | 8.67 | 7.17 | 4.34 | 4.06 | 3.25 | 3.10 | 1.76 | 1.39 | 13.20 | 15.48 | 13.79 | 15.41 | 19.34 | 4.43 | 1.80 | 3.57 | 4.45 | 2.65 | 8.76 | 9.47 | 9.85 | 11.15 | 8.04 | 8.62 | 7.35 | 5.81 | 8.00 | 7.01 | 7.06 | 7.31 | 7.55 | 7.85 | 8.18 | 8.37 | 8.42 | 8.06 | 7.82 | 7.57 | 7.27 | 7.66 | 8.81 | 9.19 | 9.39 | 9.40 | 9.13 | 9.12 | 9.04 | 9.01 | 9.20 | 9.36 | 10.49 | 2.81 | 2.22 | 3.06 |
ROA % |
8.99 | 8.45 | 8.83 | 8.34 | 8.81 | 6.73 | 7.54 | 6.07 | 4.99 | 3.01 | 2.82 | 3.14 | 1.63 | 0.71 | 7.93 | 8.12 | 9.69 | 8.56 | 9.51 | 11.82 | 2.62 | 1.05 | 2.12 | 2.69 | 1.68 | 5.30 | 5.91 | 6.35 | 7.37 | 5.45 | 5.73 | 4.81 | 3.71 | 5.13 | 4.44 | 4.43 | 4.55 | 4.65 | 4.81 | 4.99 | 5.08 | 5.08 | 5.03 | 5.02 | 5.00 | 4.97 | 5.28 | 6.10 | 6.39 | 6.57 | 6.60 | 6.44 | 6.45 | 6.42 | 6.37 | 6.49 | 6.60 | 7.39 | 1.99 | 1.57 | 2.16 |
ROCE % |
13.54 | 12.24 | 11.59 | 11.08 | 9.44 | 6.38 | 7.85 | 7.11 | 5.87 | 4.18 | 4.65 | 3.68 | 3.67 | 2.53 | 3.94 | 4.99 | 6.36 | 4.80 | 5.69 | 5.85 | 6.33 | 4.45 | 6.57 | 6.53 | 6.26 | 6.30 | 6.52 | 7.16 | 7.51 | 7.65 | 7.63 | 7.54 | 7.61 | 7.70 | 8.02 | 8.21 | 8.67 | 9.04 | 9.60 | 10.20 | 10.51 | 10.64 | 10.19 | 10.01 | 9.71 | 9.26 | 9.39 | 10.18 | 10.46 | 10.48 | 10.72 | 10.46 | 10.48 | 10.40 | 9.99 | 10.39 | 10.68 | 12.67 | 2.93 | 2.79 | 4.23 |
Current Ratio |
3.8 | 3.6 | 3.1 | 2.9 | 2.9 | 2.8 | 2.7 | 3.4 | 3.4 | 3.3 | 3.2 | 3.2 | 3.3 | 3.2 | 3.1 | - | 3.0 | 2.8 | 2.8 | 2.7 | 2.5 | 2.4 | 2.4 | 2.4 | 2.4 | 2.5 | 2.5 | 2.5 | 2.5 | 3.1 | 3.1 | 3.1 | 3.1 | 2.8 | 2.8 | 2.8 | 2.8 | 2.6 | 2.6 | 2.6 | 2.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
30.8 | 32.3 | 32.7 | 34.5 | 33.8 | - | 31.9 | 35.7 | 36.0 | - | 32.2 | 33.0 | 34.4 | - | 16.7 | 17.1 | 32.4 | - | 32.5 | 33.3 | 33.4 | - | 32.6 | 31.3 | 32.5 | 33.4 | 34.3 | 34.3 | 35.0 | 35.7 | 36.0 | 36.7 | 34.6 | 32.1 | 32.8 | 33.2 | 32.4 | - | 4170.0 | 4663.1 | 5051.4 | - | 4989.4 | 6051.8 | 6643.5 | - | 5088.0 | 4132.4 | 3785.0 | - | 631.3 | 993.4 | 1947.6 | - | 696.8 | 1150.1 | 2381.9 | - | 882.2 | 1341.1 | - |
DIO |
3.3 | 3.3 | 3.1 | 3.2 | 3.4 | - | 3.1 | 3.4 | 3.5 | - | 3.6 | 3.6 | 3.8 | - | 1.9 | 2.2 | 4.6 | - | 4.5 | 4.7 | 5.2 | - | 5.3 | 5.1 | 5.0 | - | 4.5 | 4.6 | 4.8 | - | 4.6 | 4.7 | 4.8 | - | 4.5 | 4.6 | 4.8 | - | 4.9 | 5.1 | 5.3 | - | 5.1 | 5.2 | 5.3 | - | 5.0 | 5.2 | 5.4 | - | 5.7 | 6.0 | 5.9 | - | 5.7 | 5.8 | 6.0 | - | 6.3 | 6.5 | - |
DPO |
8.1 | 8.5 | 8.6 | 8.7 | 9.4 | - | 9.5 | 10.8 | 9.9 | - | 7.7 | 7.2 | 8.1 | - | 5.1 | 6.7 | 12.9 | - | 14.8 | 11.2 | 11.4 | - | 12.7 | 12.3 | 12.4 | - | 11.3 | 11.7 | 12.5 | - | 12.1 | 12.4 | 11.6 | - | 10.0 | 10.2 | 11.4 | - | 12.1 | 12.6 | 13.6 | - | 13.6 | 13.9 | 13.1 | - | 11.2 | 11.5 | 11.0 | - | 10.5 | 10.9 | 10.1 | - | 9.0 | 9.2 | 8.7 | - | 8.4 | 8.6 | - |
Operating Cycle |
- | - | 35.8 | 37.8 | 37.2 | - | 35.0 | 39.1 | 39.5 | - | 35.8 | 36.6 | 38.2 | - | 18.6 | 19.4 | 37.0 | - | 36.9 | 38.0 | 38.6 | - | 37.9 | 36.4 | 37.6 | 33.4 | 38.8 | 38.9 | 39.8 | 35.7 | 40.6 | 41.4 | 39.3 | 32.1 | 37.3 | 37.7 | 37.2 | - | 4174.8 | 4668.2 | 5056.7 | - | 4994.5 | 6057.0 | 6648.8 | - | 5093.0 | 4137.5 | 3790.4 | - | 637.1 | 999.4 | 1953.5 | - | 702.4 | 1155.9 | 2388.0 | - | 888.5 | 1347.6 | - |
Cash Conversion Cycle |
- | - | 27.2 | 29.1 | 27.8 | - | 25.5 | 28.3 | 29.5 | - | 28.1 | 29.5 | 30.1 | - | 13.5 | 12.6 | 24.0 | - | 22.1 | 26.8 | 27.2 | - | 25.2 | 24.1 | 25.2 | 33.4 | 27.5 | 27.3 | 27.3 | 35.7 | 28.5 | 29.0 | 27.7 | 32.1 | 27.3 | 27.5 | 25.8 | - | 4162.8 | 4655.6 | 5043.1 | - | 4980.9 | 6043.1 | 6635.7 | - | 5081.8 | 4126.0 | 3779.4 | - | 626.6 | 988.5 | 1943.5 | - | 693.4 | 1146.7 | 2379.2 | - | 880.1 | 1339.0 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company National HealthCare Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Russia
USA
China
Germany
Britain
